EDITOR’S LETTER: Charles B. Nemeroff, MD, PhD

Welcome! Or should I say welcome back! Many of you remember Psychopharmacology Bulletin when it was a United States government publication which contained topical reviews and expanded abstracts of annual research meetings, such as the American College of Neuropsychopharmacology (ACNP) and the New Clinical Drug Evaluation Unit (NCDEU). I had the privilege of serving on its editorial board for many years. When the National Institute of Mental Health (NIMH) decided to largely divest itself from the publishing business, it left an opening too good to pass up. With the encouragement of the publisher of MedWorks Media, Mr. James M. La Rossa Jr., the two of us explored the possibility of reintroducing the journal, with an entirely new format. The result is before you—the first of four quarterly published issues of a journal for the practicing psychopharmacologist. Together with four superbly talented associate editors, we intend to provide to you succinct, yet comprehensive reviews on cutting-edge issues in psychopharmacology. Each issue will have reviews on translational neuroscience (Stanley J. Watson, MD, PhD, University of Michigan, associate editor), drug-drug interactions and pharmacokinetics (C. Lindsay DeVane, PharmD, Medical University of South Carolina, associate editor), complicated clinical cases (Philip T. Ninan, MD, Emory University, associate editor), and brain imaging (Clinton D. Kilts, PhD, Emory University, associate editor). Other timely reviews outside of these broad areas, but of interest to clinical practice, will also appear. We shall limit our content to reviews because we are well aware of the plethora of excellent peer reviewed journals in this field that focus on original research contributions. We intend to also publish supplements, which bridge cutting-edge issues in psychopharmacology, as well as meeting proceedings. The associate editors and I are joined by a small but extraordinarily talented group of editorial board members, all chosen because of their unique contributions to the field, and willingness to contribute to the success of the journal. Our goal is to produce a journal that is the practitioner’s friend, a topical guidebook to the science and art of psychopharmacology. I look forward to receiving comments from you, the reader, as to how successful we are in achieving this goal, as well as receiving suggestions for articles of particular interest to you.